The Brazilian Health Regulatory Agency (ANVISA) granted approval for the FlareHawk7 and FlareHawk9 spine implant devices.

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled SAN FRANCISCO and BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., ...

PHILADELPHIA, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is also pleased to announce that its phase 2 clinical study (SKNJCT-003) which is ...

Apogee begins patient dosing in Part B of phase 2 APEX trial of APG777 to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 4, 2025, 18:00 Hrs [IST] Apog ...

Molecular communications in the bloodstream is a promising area of research, since the bloodstream has the ability to ...

Dezeen School Shows: we've rounded up seven student projects featured in Dezeen School Shows that utilise modern technology ...

Johnson & Johnson has launched the TECNIS PureSee™ intraocular lens in India, catering to individuals with presbyopia. The ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Design Therapeutics' GeneTAC platform is revolutionizing genetic disease treatment with small molecules and promising results in Friedreich's ataxia. See more here.

Contributor content. As a health care IT specialist, Vedamurthy Yogeshappa uses Artificial Intelligence (AI) to streamline ...

For part 3 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the favorable safety ...

Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today presented novel research evaluating the patient experience and barriers to enrollment and participation in cell and ...